76 related articles for article (PubMed ID: 15215159)
1. Sodium iodide symporter immunolabelling as a predictor of clinical iodide uptake in canine thyroid carcinoma: A preliminary study.
Dark KV; Skinner OT; Kim DY; Karnia JJ; Mickelson MA; Maitz CA
Vet Comp Oncol; 2024 Jun; 22(2):239-244. PubMed ID: 38488259
[TBL] [Abstract][Full Text] [Related]
2. Function and Clinical Significance of Circular RNAs in Thyroid Cancer.
Yao X; Zhang Q
Front Mol Biosci; 2022; 9():925389. PubMed ID: 35936780
[TBL] [Abstract][Full Text] [Related]
3. Analysis of NIS Plasma Membrane Interactors Discloses Key Regulation by a SRC/RAC1/PAK1/PIP5K/EZRIN Pathway with Potential Implications for Radioiodine Re-Sensitization Therapy in Thyroid Cancer.
Faria M; Domingues R; Bugalho MJ; Silva AL; Matos P
Cancers (Basel); 2021 Oct; 13(21):. PubMed ID: 34771624
[TBL] [Abstract][Full Text] [Related]
4. Mechanisms of regulating NIS transport to the cell membrane and redifferentiation therapy in thyroid cancer.
Cai X; Wang R; Tan J; Meng Z; Li N
Clin Transl Oncol; 2021 Dec; 23(12):2403-2414. PubMed ID: 34100218
[TBL] [Abstract][Full Text] [Related]
5. Implications of Na
Martín M; Geysels RC; Peyret V; Bernal Barquero CE; Masini-Repiso AM; Nicola JP
J Endocr Soc; 2019 Jan; 3(1):222-234. PubMed ID: 30620007
[TBL] [Abstract][Full Text] [Related]
6. A Carboxy-Terminal Monoleucine-Based Motif Participates in the Basolateral Targeting of the Na+/I- Symporter.
Martín M; Modenutti CP; Peyret V; Geysels RC; Darrouzet E; Pourcher T; Masini-Repiso AM; Martí MA; Carrasco N; Nicola JP
Endocrinology; 2019 Jan; 160(1):156-168. PubMed ID: 30496374
[TBL] [Abstract][Full Text] [Related]
7. Clinical Significance of Thyroid-Stimulating Hormone Receptor Gene Mutations and/or Sodium-Iodine Symporter Gene Overexpression in Indeterminate Thyroid Fine Needle Biopsies.
Guan H; Matonis D; Toraldo G; Lee SL
Front Endocrinol (Lausanne); 2018; 9():566. PubMed ID: 30319546
[No Abstract] [Full Text] [Related]
8. NIS expression in thyroid tumors, relation with prognosis clinicopathological and molecular features.
Tavares C; Coelho MJ; Eloy C; Melo M; da Rocha AG; Pestana A; Batista R; Ferreira LB; Rios E; Selmi-Ruby S; Cavadas B; Pereira L; Sobrinho Simões M; Soares P
Endocr Connect; 2018 Jan; 7(1):78-90. PubMed ID: 29298843
[TBL] [Abstract][Full Text] [Related]
9. A Concise Atlas of Thyroid Cancer Next-Generation Sequencing Panel ThyroSeq v.2.
Alsina J; Alsina R; Gulec S
Mol Imaging Radionucl Ther; 2017 Feb; 26(Suppl 1):102-117. PubMed ID: 28117295
[TBL] [Abstract][Full Text] [Related]
10. Association between sodium iodide symporter and differentiated Thyroid cancer: a meta-analysis of 9 studies.
Zhang R; Wang H; Zhao J; Yao J; Shang H; Zhu H; Liao L; Dong J
Int J Clin Exp Med; 2015; 8(10):17986-94. PubMed ID: 26770393
[TBL] [Abstract][Full Text] [Related]
11. Sodium iodide symporter (NIS) in extrathyroidal malignancies: focus on breast and urological cancer.
Micali S; Bulotta S; Puppin C; Territo A; Navarra M; Bianchi G; Damante G; Filetti S; Russo D
BMC Cancer; 2014 Apr; 14():303. PubMed ID: 24884806
[TBL] [Abstract][Full Text] [Related]
12. Methylation levels of sodium-iodide symporter (NIS) promoter in benign and malignant thyroid tumors with reduced NIS expression.
Galrão AL; Sodré AK; Camargo RY; Friguglietti CU; Kulcsar MA; Lima EU; Medeiros-Neto G; Rubio IG
Endocrine; 2013 Feb; 43(1):225-9. PubMed ID: 22945693
[TBL] [Abstract][Full Text] [Related]
13. Propylthiouracil increases sodium/iodide symporter gene expression and iodide uptake in rat thyroid cells in the absence of TSH.
Sue M; Akama T; Kawashima A; Nakamura H; Hara T; Tanigawa K; Wu H; Yoshihara A; Ishido Y; Hiroi N; Yoshino G; Kohn LD; Ishii N; Suzuki K
Thyroid; 2012 Aug; 22(8):844-52. PubMed ID: 22853729
[TBL] [Abstract][Full Text] [Related]
14. Muc-1 expression may help characterize thyroid nodules but does not predict patients' outcome.
Morari EC; Silva JR; Guilhen AC; Cunha LL; Marcello MA; Soares FA; Vassallo J; Ward LS
Endocr Pathol; 2010 Dec; 21(4):242-9. PubMed ID: 21057891
[TBL] [Abstract][Full Text] [Related]
15. A novel mechanism of sodium iodide symporter repression in differentiated thyroid cancer.
Smith VE; Read ML; Turnell AS; Watkins RJ; Watkinson JC; Lewy GD; Fong JC; James SR; Eggo MC; Boelaert K; Franklyn JA; McCabe CJ
J Cell Sci; 2009 Sep; 122(Pt 18):3393-402. PubMed ID: 19706688
[TBL] [Abstract][Full Text] [Related]
16. Human thyroid tumours, the puzzling lessons from E7 and RET/PTC3 transgenic mice.
Jin L; Burniat A; Dumont JE; Miot F; Corvilain B; Franc B
Br J Cancer; 2008 Dec; 99(11):1874-83. PubMed ID: 18985036
[TBL] [Abstract][Full Text] [Related]
17. Distribution of Na+/I- symporter in thyroid cancers in an iodine-deficient population: an immunohistochemical study.
Mishra A; Pal L; Mishra SK
World J Surg; 2007 Sep; 31(9):1737-1742. PubMed ID: 17653791
[TBL] [Abstract][Full Text] [Related]
18. Relationship of sodium/iodide symporter expression with I131 whole body scan uptake between primary and metastatic lymph node papillary thyroid carcinomas.
Lee SJ; Choi KC; Han JP; Park YE; Choi MG
J Endocrinol Invest; 2007 Jan; 30(1):28-34. PubMed ID: 17318019
[TBL] [Abstract][Full Text] [Related]
19. Evidence for transcriptional and posttranscriptional alterations of the sodium/iodide symporter expression in hypofunctioning benign and malignant thyroid tumors.
Trouttet-Masson S; Selmi-Ruby S; Bernier-Valentin F; Porra V; Berger-Dutrieux N; Decaussin M; Peix JL; Perrin A; Bournaud C; Orgiazzi J; Borson-Chazot F; Franc B; Rousset B
Am J Pathol; 2004 Jul; 165(1):25-34. PubMed ID: 15215159
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
